Position in ACAD
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,219,241
+$1,382,486 QoQ
Shares Held
144,620
+68.0% QoQ
Ownership
0.084%
of shares outstanding
% of Portfolio
0.63%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
4 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ACAD Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Tetragon Partners GP Ltd holds $113,244,734 across 25 Biotechnology names. ACAD ranks #18 (2.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AUTL |
Autolus Therapeutics plc
|
9,500,000 | $13,110,000 | |
| 2 | CLDX |
Celldex Therapeutics, Inc.
|
312,316 | $9,906,663 | |
| 3 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
127,198 | $7,975,314 | |
| 4 | NKTR |
Nektar Therapeutics
|
103,037 | $7,413,512 | |
| 5 | ANNX |
Annexon, Inc.
|
1,292,455 | $7,160,200 | |
| 6 | PHVS |
Pharvaris N.V.
|
221,611 | $6,260,510 | |
| 7 | AGIO |
Agios Pharmaceuticals, Inc.
|
164,839 | $5,576,503 | |
| 8 | IMVT |
Immunovant, Inc.
|
218,507 | $5,427,713 |
All Filings in ACAD
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,219,241 | 144,620 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | $1,836,755 | 86,071 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $3,481,311 | 161,396 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $1,777,270 | 107,000 | Shares | Defined | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||